Measles Testing: Laboratory Methods, Specimen Timing, and Outbreak Confirmation

Last Updated: May 2026, This article has been substantially updated to reflect the 2025 US measles outbreak (1,514 confirmed cases as of September 2025, the highest since 1992); current CDC and APHL laboratory guidance on specimen collection timing and RT-PCR protocols; the MeVA vaccine-specific RT-PCR assay; IgM false-negative windows; testing in vaccinated individuals; genotyping for outbreak investigation; wastewater surveillance; and mandatory reporting requirements.

⚡ Quick Take

• Real-time RT-PCR (rRT-PCR) and IgM serology are both recommended for all suspected measles cases. Collect specimens concurrently at first clinical contact, before the patient leaves the facility.
• IgM testing may be false-negative in up to 23% of cases collected within 72 hours of rash onset; a second specimen collected ≥72 hours after rash onset is recommended if the initial result is negative.
• RT-PCR is most sensitive within the first 3 days of rash; use synthetic (non-cotton) nasopharyngeal or throat swabs in viral transport medium. Urine is an alternative specimen.
• The MeVA (Measles Vaccine-specific RT-PCR) assay distinguishes wild-type measles virus from vaccine strain, critical when the patient received MMR within 21 days of rash onset.
• Measles is a mandatory, immediately notifiable disease in the US; contact the local health department before the patient leaves the clinical facility.

Measles in 2025: Why Laboratory Testing Has Become Urgently Relevant Again

Accurate laboratory confirmation of measles is the difference between a contained case and a community outbreak, and in 2025, that distinction became more consequential than at any point since 1992. The final 2025 tally of 2,288 confirmed measles cases across 45 US jurisdictions, verified by CDC surveillance data, is the highest annual total since 1991, surpassing the 1992 outbreak that had previously defined the modern high-water mark. Three measles-associated deaths were confirmed, all in unvaccinated individuals, marking the first US measles fatalities in over a decade. Eleven percent of patients required hospitalization, consistent across multiple surveillance cycles per the CDC’s April 2025 MMWR report, with the highest rates among children under five years of age (21%). About 93% of confirmed cases occurred in people who were unvaccinated or whose vaccination status was unknown.

The 2025 resurgence has a clear, documented driver. US kindergarten MMR vaccination coverage declined to 92.5% in the 2024–2025 school year, down from 95.2% in 2019–2020, per the CDC’s VaxView surveillance system, leaving an estimated 286,000 kindergartners potentially susceptible. This coverage level falls below the ≥95% community immunity threshold established by WHO and CDC for a pathogen with a basic reproduction number (R₀) of 12–18, one of the highest of any known human pathogen, per the NEJM 2025 measles review. The primary cause of the resurgence is failure to vaccinate, not failure of the vaccine: one dose of MMR is 93% effective, and two doses are 97% effective.

For the most current clinical guidance, see CDC Laboratory Testing for Measles and the CDC/APHL Measles Serology Testing guidance.

Measles Virus Biology: What Makes This Pathogen So Difficult to Contain

Morbillivirus hominis (measles virus) is a single-stranded, negative-sense RNA virus in the family Paramyxoviridae with an airborne transmission route and a pre-rash infectious period that begins 4 days before the rash appears, the period when most secondary transmission occurs. Measles’ extraordinary communicability (R₀ = 12–18) means that a single unvaccinated individual in a susceptible population can infect 12–18 others, and that maintaining herd immunity requires immunizing ≥95% of the population. A community where just 5% of individuals are unvaccinated is epidemiologically vulnerable.

The clinical presentation, the 3 C’s (cough, coryza, conjunctivitis) followed by Koplik’s spots (pathognomonic white spots on the buccal mucosa) and then a descending maculopapular rash, is classic in unvaccinated, immunocompetent individuals. However, modified measles in previously vaccinated or partially immune individuals may present with attenuated or absent rash, shorter illness, and atypical laboratory findings that make clinical diagnosis unreliable without confirmatory testing. This is one of the primary reasons laboratory confirmation is required for all suspected cases, not just clinically typical presentations.

Complications of measles include: pneumonia (the most common cause of measles-related death, occurring in approximately 1 in 20 cases); measles encephalitis (1 in 1,000 cases); subacute sclerosing panencephalitis (SSPE), a delayed fatal neurodegenerative complication occurring years after acute infection, in approximately 1 per 1,000–2,000 cases, with higher rates in children infected before age 2; and immune amnesia, measles infection suppresses the immune system’s memory for other pathogens, increasing susceptibility to secondary infections for months to years after recovery.

Measles Laboratory Testing Methods: Serology, RT-PCR, Genotyping, and Reference Assays

The four core laboratory methods for measles are not interchangeable; they answer different diagnostic questions and are optimal at different time points relative to symptom onset. Understanding when and why to use each method determines whether a case is confirmed, remains suspected, or generates a misleading result.

How Should Measles Testing Specimens Be Collected, and When?

Specimen timing relative to rash onset is the single most important variable in measles laboratory diagnosis. The right test ordered from the wrong specimen collected at the wrong time produces results, including false negatives, that can delay outbreak response and create false assurance. Current CDC laboratory guidance provides the following framework:

At First Clinical Contact (Ideally Before Patient Leaves the Facility)

Collect both a serum sample for IgM serology AND a nasopharyngeal or throat swab for rRT-PCR simultaneously. The two tests are complementary, rRT-PCR is most sensitive in the first 72 hours when IgM serology may be falsely negative; after day 3, IgM sensitivity increases while PCR sensitivity begins to decline. Performing both together maximizes the probability of confirmation at any presentation time point.

Specific collection requirements:

• Serum for IgM and IgG: Draw 1–2 mL blood in a red-top tube. For young children where venipuncture is not preferred, 50–100 μL capillary blood (~3 capillary tubes) is acceptable. Separate serum if possible; refrigerate at 2–8°C.
• Nasopharyngeal or throat swab for rRT-PCR: Use synthetic (non-cotton) swabs, Dacron® or Copan swabs (without charcoal). Standard cotton swabs contain compounds that inhibit PCR amplification. Place in 1–3 mL of commercially available viral transport medium (VTM). Refrigerate immediately; do not freeze. Collect within the first 3 days of rash onset for the highest sensitivity, and not more than 10 days after rash onset.
• Urine: An alternative rRT-PCR specimen. Collect 10–50 mL of clean-catch urine in a sterile container. Refrigerate immediately. Urine can be a useful option when nasopharyngeal/throat swabs are impractical, particularly for children.

If Initial IgM Is Negative and Collected Within 72 Hours of Rash Onset

Collect a second serum specimen at 72 hours or more after rash onset. The IgM response is not detectable in some cases until 3 days after rash onset, and false-negative rates from early-collected specimens can reach 23%. A negative IgM from a specimen collected within the first 72 hours should not be used to exclude measles in a clinically or epidemiologically compatible case.

For Immunity Assessment (Not Acute Diagnosis)

A single IgG test is appropriate for determining whether a person has measles antibodies, indicating past infection or vaccination. IgG is not a useful test for acute measles diagnosis; it cannot confirm acute infection from a single specimen (requires paired acute and convalescent specimens showing a fourfold or greater rise in titer, collected 14–30 days apart).

Shipping: Specimens must be shipped overnight to the receiving laboratory at 2–8°C with cold packs. Do not ship over weekends or holidays. Specimens must arrive within 8 days of collection. Incorrectly labeled specimens will be rejected. Contact the local or state health department before shipping.

Serology Testing: IgM for Acute Diagnosis, IgG for Immunity Assessment

Serology is the most widely accessible measles diagnostic method; IgM and IgG testing is available through commercial reference laboratories, while rRT-PCR requires referral to public health laboratories for most providers.

Measles IgM: Detecting Acute Infection

Measles-specific IgM antibodies are the primary serologic marker of acute infection. A capture IgM EIA incorporating recombinant measles nucleocapsid protein is used at CDC, and reference laboratories; commercial indirect EIA platforms are widely available for initial screening. Interpretation rules:

• IgM positive (≥72 hours after rash onset): Provides strong presumptive evidence of current or recent measles infection. Confirm with rRT-PCR where available, for definitive case classification.
• IgM negative (<72 hours after rash onset): Should be interpreted with caution, up to 23% false-negative rate in this window. Repeat collection recommended.
• IgM positive (in elimination settings): In the US and other countries where measles has been declared eliminated, the positive predictive value of IgM decreases substantially because the pre-test probability of true measles is low. False-positive IgM results due to cross-reactivity with Parvovirus B19, rubella, and human herpesvirus 6 (HHV-6) are more common than true measles positives in these settings. Every IgM-positive result in an elimination setting should trigger concurrent rRT-PCR and clinical case review before public health notification is completed.

Measles IgM remains detectable for approximately 6–8 weeks after rash onset. Testing outside this window typically returns negative results even from confirmed measles cases.

Measles IgG: Assessing Immunity Status

A single IgG test cannot confirm acute measles; it determines whether a person has protective antibodies from vaccination or prior infection. IgG assays are appropriate for:

• Pre-exposure immunity assessment in healthcare workers, travelers, and individuals with uncertain vaccination history.
• Outbreak contact investigation: identifying susceptible individuals who may benefit from post-exposure prophylaxis (PEP) with MMR vaccine or immunoglobulin (IG).
• Paired acute/convalescent IgG for case confirmation when IgM is unavailable, or results are inconclusive: a fourfold or greater rise in IgG titer between specimens drawn 14–30 days apart constitutes supportive evidence of recent infection.

IgG generally becomes detectable 7–10 days after rash onset, peaks at approximately 2 weeks, and persists for life in individuals with durable immunity.

RT-PCR: Molecular Confirmation and the MeVA Vaccine-Strain Assay

Real-time RT-PCR (rRT-PCR) is the most sensitive method for early confirmation of measles infection and is required for case classification in most outbreak settings. Most commercial clinical laboratories do not perform measles rRT-PCR; this testing is primarily available through state and local public health laboratories and through the APHL Vaccine Preventable Diseases Reference Centers. Contact the local or state health department to determine the referral pathway in your jurisdiction.

Standard Measles rRT-PCR

rRT-PCR detects measles viral RNA in nasopharyngeal swabs, throat swabs, and urine specimens. Sensitivity is highest within the first 3 days after rash onset, and RT-PCR may remain positive through 10–14 days post-rash in some cases. Beyond 14 days, the likelihood of successful molecular detection declines substantially.

A 2024 CDC review of rRT-PCR performance confirmed that rRT-PCR provides definitive differentiation between wild-type virus and vaccine-related rashes, though the standard rRT-PCR assay does not alone identify vaccine strain. Identification of the vaccine strain requires the specific MeVA assay.

MeVA: The Vaccine-Specific RT-PCR Assay

When a patient with a febrile rash received the MMR vaccine within 21 days of rash onset, the clinical question changes: is this a vaccine-related rash (Moraten vaccine strain) or a true wild-type measles infection? The Measles Vaccine-specific RT-PCR assay (MeVA), developed by CDC and available through APHL reference centers, specifically distinguishes vaccine strain from wild-type measles RNA. MeVA testing requires advanced coordination with the state health department or the APHL/CDC Vaccine Preventable Disease Reference Center. Advance approval is required; contact the state health department before sending specimens.

Virus Isolation and Genotyping for Outbreak Investigation

Genotyping is not a routine diagnostic method, but is essential for public health outbreak investigation. By sequencing a portion of the measles virus genome from PCR-positive specimens, genotyping establishes whether the case is linked to other confirmed cases in the same cluster, whether the virus was imported from a specific geographic source (WHO maintains a global genotype reference database), and whether the circulating genotype represents an ongoing transmission chain or repeated importations. During active US outbreaks, the CDC’s viral genomics team performs measles genotyping on specimens from index cases and a representative sample from outbreak clusters.

Current circulating genotypes in the US have primarily been D8 and B3, imported from endemic regions including South Asia, Africa, and parts of Europe, where elimination has not been achieved. WHO’s measles genotype reference database at who-measles.org maintains sequence data enabling international source attribution for outbreak strains.

Virus isolation in cell culture (Vero/hSLAM cells) is technically possible and allows characterization of the full viral phenotype, but it is time-consuming, requires specialized biosafety infrastructure, and has been largely supplanted by molecular methods for routine diagnostic and outbreak purposes. Culture remains used at CDC for selected research and reference characterization purposes.

Interpreting Results in Vaccinated Individuals and Elimination Settings

Two scenarios generate the most diagnostic uncertainty in measles laboratory testing, and both are increasingly common in 2025: testing vaccinated individuals with atypical presentations, and testing in elimination settings where background serological noise increases false-positive rates.

Modified Measles in Vaccinated Individuals

Individuals who have received one or two doses of MMR and subsequently become infected with wild-type measles virus may develop modified measles, a milder form with attenuated or absent rash, shorter duration, and fever that may be low-grade. In these individuals:

• IgM is frequently absent or present at low levels: Modified measles often generates an anamnestic (memory) IgG response rather than a primary IgM response. A negative IgM in a vaccinated individual does not exclude measles.
• IgG rises rapidly: Secondary immune responses in previously primed individuals produce earlier, higher IgG levels, making paired acute/convalescent IgG testing less useful (the rise may be complete before a convalescent specimen is collected).
• PCR is the most reliable method: rRT-PCR can detect wild-type virus in vaccinated individuals with modified measles, provided the specimen is collected early (within the first 3 days of rash onset). All vaccinated individuals with suspected measles should have rRT-PCR in addition to serology.
• MeVA assay required if recently vaccinated: If the patient received MMR within 21 days of rash onset, the MeVA assay is required to distinguish vaccine-associated rash from true wild-type infection.

False-Positive IgM in Elimination Settings

The ARUP Consult measles testing guidance notes that in regions where measles has been declared eliminated, false-positive IgM results become more frequent relative to true positives because the prior probability of true measles is low. Cross-reactivity with parvovirus B19, rubella virus, and human herpesvirus 6 is the primary source of false-positive IgM on commercial assay platforms. Every positive IgM result in an elimination setting must be followed by confirmatory rRT-PCR and reviewed against the clinical presentation (Koplik’s spots, classic descending rash, 3 C’s) before public health case reporting is initiated.

Emerging Surveillance: Wastewater Detection of Measles Virus

Wastewater-based epidemiology (WBE), the detection of pathogen RNA in municipal wastewater, provided early warning of SARS-CoV-2 transmission before clinical case counts rose during the COVID-19 pandemic. In 2025, wastewater detection of measles virus RNA was implemented as an early surveillance tool in several US states, including California, Connecticut, and Maryland. Detection of measles RNA in wastewater provides a signal of active measles virus shedding in the community, including silent, sub-clinical, or undiagnosed cases that do not appear in routine clinical surveillance.

Wastewater measles surveillance is a complement to, not a substitute for, clinical testing; it cannot identify specific individuals, vaccination status, or case count. However, it provides public health agencies with approximately 4–7 days of advance warning before clinical measles cases are reported, allowing pre-emptive immunization campaigns and heightened clinical alertness in affected communities.

The US Measles Laboratory Network: Where Testing Happens

Measles testing in the US is organized through a tiered network of public health and reference laboratories:

• Commercial clinical laboratories: Perform IgM and IgG serology (EIA platforms). Most commercial laboratories do not perform measles rRT-PCR or genotyping. Commercial IgM-positive results typically require public health laboratory confirmation in suspected outbreak contexts.
• State and local public health laboratories: Primary access point for rRT-PCR testing. Most state public health laboratories perform or refer measles rRT-PCR testing. Contact the health department in the jurisdiction where the case presents before ordering rRT-PCR.
• APHL Vaccine Preventable Diseases (VPD) Reference Centers: A network of regional reference laboratories maintained by the Association of Public Health Laboratories (APHL) that provide rRT-PCR, MeVA, and genotyping services for jurisdictions without full in-house capability. Access via state health department referral.
• CDC Infectious Diseases Laboratory (Atlanta): Provides genotyping, IgG avidity, PRN (plaque reduction neutralization) assay, MeVA, and outbreak support testing. Access requires advance approval from the CDC Viral Vaccine Preventable Diseases Branch, coordinated through the state health department. During active outbreaks, the CDC can assist with testing for highly suspicious cases.

What Positive Results Require: Mandatory Reporting and Public Health Action

Measles is a mandatory, immediately notifiable disease in the United States. For confirmed cases, and in most jurisdictions for suspected cases, healthcare providers and laboratories are required to notify the local or state health department before the patient leaves the clinical facility, where possible. The CDC’s 2025 MMWR measles update emphasizes that prompt notification enables rapid contact tracing, identification of susceptible contacts, and deployment of post-exposure prophylaxis (PEP) before secondary transmission occurs.

Laboratory-confirmed measles cases must be reported using the National Notifiable Diseases Surveillance System (NNDSS) case definition, which requires either: a clinically compatible illness plus epidemiologic linkage to a laboratory-confirmed case; OR laboratory confirmation regardless of clinical presentation. A clinical case that meets the clinical case definition but cannot be confirmed by laboratory testing, and is not linked to a confirmed case, is classified as probable measles.

The CDC 7-1-7 framework, detect a cluster within 7 days, begins investigation within 1 day, and completes initial control within 7 days, sets the timeliness benchmark for measles outbreak response. Laboratory turnaround time is a direct determinant of whether a jurisdiction meets this response standard.

Finding Laboratories for Measles Testing and Outbreak Support

ContractLaboratory.com connects hospitals, clinics, public health agencies, and testing organizations with microbiology and pathogen detection laboratories, medical and clinical testing specialists, genetics and genomic testing facilities (for measles genotyping), and biology and life sciences testing laboratories

Frequently Asked Questions About Measles Testing

Conclusion: Laboratory Testing as the Foundation of Outbreak Control

Measles cannot be controlled by surveillance alone, it requires laboratory confirmation fast enough to activate contact tracing before secondary transmission occurs. The 2025 US outbreak, with 1,514 cases and three deaths, demonstrates what happens when vaccination coverage falls below the herd immunity threshold in a country that had sustained measles elimination for over two decades. For laboratory professionals and public health testing organizations, this means understanding not just which test to order, but when to collect the specimen, which laboratory network to route it through, and how to interpret results in vaccinated individuals and elimination settings where standard interpretive frameworks can mislead.

ContractLaboratory.com connects public health agencies, hospitals, and clinical organizations with specialized microbiology and pathogen detection laboratories for measles diagnostic support. Submit a testing request or contact our team.